Bosutinib is a second-generation dual Abl/Src inhibitor that exhibits potent growth inhibition of CML cells in vitro, is active against multiple imatinib-resistant BCR-Abl mutations and has demonstrated efficacy in ongoing clinical trials for imatinib-resistant CML [11], [12], [13]. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.